

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 10, 2007

---

**VICAL INCORPORATED**

(Exact name of registrant as specified in charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-21088**  
(Commission File Number)

**93-0948554**  
(I.R.S. Employer  
Identification No.)

**10390 Pacific Center Court**  
**San Diego, California**  
(Address of principal executive offices)

**92121-4340**  
(Zip Code)

Registrant's telephone number, including area code: (858) 646-1100

**Not Applicable.**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

---

**Item 1.02 Termination of a Material Definitive Agreement.**

On April 10, 2007, Vical Incorporated entered into a Termination Agreement with Vascular Genetics, Inc., a predecessor of Corautus Genetics, Inc., which immediately terminated the License Agreement dated February 24, 2000 between Vical and Vascular Genetics. Under the License Agreement, Vical had granted a license to its core DNA delivery technology for specific cardiovascular applications in exchange for potential royalty payments if Vascular Genetics developed products using the license.

In connection with the termination, Vical and Vascular Genetics also agreed to release each other from all claims arising under the License Agreement.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 18, 2007

**VICAL INCORPORATED**

By: /s/ JILL M. CHURCH

Jill M. Church

Vice President, Chief Financial Officer and Secretary